News / Finance
Easton Pharmaceuticals Announces VIORRA Regulatory Filing in Mexico: Expected to be First Territory Launch
An over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal FSAD (Female Sexual Arousal Disorder), VIORRA is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.
-- "Our market analysis reveals that Mexico represents an ideal first territory launch site for our VIORRA Female Sexual Dysfunction (FSAD) product," says John Easton, Easton Pharmaceuticals' CEO and Chairman of the board "As Male Sexual Dysfunction products have historically done very well in Mexico, and with a population of 120 million, the raw numbers of prospective female customers are very attractive to Easton Pharmaceuticals. The world market for these female conditions are in excess of $2 billion." -- BMV estimates the regulatory process to require six to seven months until a marketing approval is obtained. In parallel with the regulatory filing, Easton Pharmaceuticals has begun talks with several large distribution companies focused on sales and marketing in the women's health, sexual arousal disorder and the sexual wellness market. Easton Pharmaceuticals" believes with both the regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of VIORRA in Mexico in early 2012.
About Easton Pharmaceuticals Inc.
Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world market for these conditions is in excess of $10 billion.
The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal moisture and elasticity which has a very positive effect on women's sexual desire and arousal, FSAD (Female Sexual Arousal Disorder) the world market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.
For More Information Visit http://www.eastonpharma.com
Safe Harbor
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings.
Copyright ©2011 Easton Pharmaceuticals Inc. All rights reserved. Easton Pharmaceuticals, Easton Pharma and the Easton Pharmaceuticals logo, and all other Easton Pharmaceuticals company, product, and services names and slogans are trademarks or registered trademarks of Easton Pharmaceuticals Inc.
